The board (the "Board") of directors of Shanghai Junshi Biosciences Co., Ltd. announce that Dr. Li Ning ("Dr. Li") has been elected as the vice chairman of the third session of the Board with effect from the date of this announcement to the conclusion of the term of the third session of the Board. Dr. Li shall also serve as the chairman of the board of directors of TopAlliance Biosciences Inc., being a wholly-owned subsidiary of the Company, and shall be responsible for the overseas business of the Company. Dr. Li Ning aged 62, has been an executive Director since June 2018.

From January 2018 to January 2024, he has served as the chief executive officer and general manager of the Company. Since December 2023, he has served as the director of TA BIOSCIENCES PTE. LTD., being a wholly-owned subsidiary of the Company.

Dr. Li's main experience prior to joining the Group includes: he held various positions, including team leader of the Office of Biostatistics, team leader of mathematical statistician and a statistical reviewer at the U.S. Food and Drug Administration; he was employed by Sanofi from September 2009 to January 2018, and the last position he held was Vice President Asia Regulatory Affairs in Global Regulatory Affairs; from November 2010 to November 2012, he was a guest professor at the Clinical Research Institute of Peking University and from January 2012 to December 2014, he was a part-time professor at the Medical Informatics Center of Peking University. Dr. Li obtained his bachelor's degree in public health from Shanghai Medical College of Fudan University, the PRC in July 1984 and his master's degree in medicine from Shanghai Medical College of Fudan University, the PRC in October 1987. He obtained his Ph.D. degree in preventive medicine from University of Iowa, the United States in August 1994.